These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 22085320)
61. Intensive lipid-lowering therapy: obvious benefits, possible risks. Zimlichman E; Szyper-Kravitz M; Katz U; Shoenfeld Y Isr Med Assoc J; 2006 Dec; 8(12):890-1. PubMed ID: 17214117 [No Abstract] [Full Text] [Related]
62. Statin myopathy: a review of recent progress. Mammen AL; Amato AA Curr Opin Rheumatol; 2010 Nov; 22(6):644-50. PubMed ID: 20827205 [TBL] [Abstract][Full Text] [Related]
63. Summaries for patients. Red yeast rice to treat cholesterol problems in patients who cannot tolerate statin therapy because of muscle pain. Ann Intern Med; 2009 Jun; 150(12):I28. PubMed ID: 19528545 [No Abstract] [Full Text] [Related]
64. Risks in the balance: the statins row. Hawkes N BMJ; 2014 Aug; 349():g5007. PubMed ID: 25103564 [No Abstract] [Full Text] [Related]
65. Toxicity of antilipidemic agents: facts and fictions. Xydakis AM; Jones PH Curr Atheroscler Rep; 2003 Sep; 5(5):403-10. PubMed ID: 12911851 [No Abstract] [Full Text] [Related]
74. Statin guidelines should give best statin. Moriguchi H; Uemura T; Sato C BMJ; 2006 Jul; 333(7557):46. PubMed ID: 16809724 [No Abstract] [Full Text] [Related]
75. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents]. Soska V Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414 [TBL] [Abstract][Full Text] [Related]
76. [Persistent CK-elevation after CSE inhibitor therapy]. Faehling M; Leschke M Dtsch Med Wochenschr; 2006 Aug; 131(33):1827-8. PubMed ID: 16902911 [No Abstract] [Full Text] [Related]